Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
THE AUSTRALIAN MULTICENTER DOUBLE-BLIND COMPARATIVE-STUDY OF REMOXIPRIDE AND THIORIDAZINE IN SCHIZOPHRENIA
Autore:
KEKS N; MCGRATH J; LAMBERT T; CATTS S; VADDADI K; BURROWS G; VARGHESE F; GEORGE T; HUSTIG H; BURNETT P; KERR K; ZORBAS A; HILL C; STEDMAN T; JOHNSON G; LEIBERT B; COPOLOV D; MACKENZIE M; DILLENBECK C;
Indirizzi:
ALFRED HOSP,COMMERCIAL RD MELBOURNE VIC 3181 AUSTRALIA WOLSTON PK HOSP BRISBANE QLD AUSTRALIA QUEEN ELIZABETH II MED CTR PERTH WA AUSTRALIA PRINCE WALES HOSP SYDNEY NSW AUSTRALIA MAROONDAH HOSP MELBOURNE VIC AUSTRALIA AUSTIN HOSP MELBOURNE VIC 3084 AUSTRALIA PRINCESS ALEXANDRA HOSP BRISBANE QLD 4102 AUSTRALIA PRINCE CHARLES HOSP BRISBANE QLD 4032 AUSTRALIA GLENSIDE HOSP ADELAIDE SA AUSTRALIA HILLCREST HOSP ADELAIDE SA AUSTRALIA ROYAL PRINCE ALFRED HOSP SYDNEY NSW AUSTRALIA SIR CHARLES GAIRDINER HOSP PERTH WA 6000 AUSTRALIA ROYAL PK HOSP MELBOURNE VIC AUSTRALIA CONCORD HOSP SYDNEY NSW AUSTRALIA ASTRA PHARMACEUT SYDNEY NSW AUSTRALIA
Titolo Testata:
Acta psychiatrica Scandinavica
fascicolo: 5, volume: 90, anno: 1994,
pagine: 358 - 365
SICI:
0001-690X(1994)90:5<358:TAMDCO>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Soggetto:
COMPARING REMOXIPRIDE; HALOPERIDOL; TRIAL; EFFICACY;
Keywords:
NEUROLEPTIC DRUG; REMOXIPRIDE; THIORIDAZINE; SCHIZOPHRENIA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social Sciences Citation Index
Science Citation Index Expanded
Citazioni:
24
Recensione:
Indirizzi per estratti:
Citazione:
N. Keks et al., "THE AUSTRALIAN MULTICENTER DOUBLE-BLIND COMPARATIVE-STUDY OF REMOXIPRIDE AND THIORIDAZINE IN SCHIZOPHRENIA", Acta psychiatrica Scandinavica, 90(5), 1994, pp. 358-365

Abstract

A double-blind, randomized study of parallel group design comparing remoxipride and thioridazine (dose range 150-600 mg/day of either drug)was undertaken at 11 Australian centres. A total of 144 patients (remoxipride = 73, thioridazine = 71) with DSM-III-R schizophrenia or schizophreniform disorder commenced the study, and 89 patients (remoxipride = 45, thioridazine = 44) completed the 6 weeks of the trial. The mean daily doses at last rating were 404 mg (remoxipride) and 378 mg (thioridazine). Initial Brief Psychiatric Rating Scale scores decreased bya mean 8.7 points in both remoxipride and thioridazine groups. Equivalent treatment responses were also confirmed by Clinical Global Impression. During the study, sedatives or hypnotics were needed by 68%, of the remoxipride patients and 51% of the thioridazine patients. Thioridazine was associated with more postural hypotension, drowsiness, increased sleep, headache, dizziness on rising, dry mouth, sexual dysfunction and weight gain, while remoxipride patients reported more insomnia. There were no differences between remoxipride and thioridazine on dystonia, hypokinesia, dyskinesia, rigidity and akathisia. The results indicate that remoxipride has similar antipsychotic efficacy to thioridazine but causes fewer side effects.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/11/20 alle ore 17:10:46